**Name of Journal: *World Journal of Gastrointestinal Pharmacology and Therapeutics***

**ESPS Manuscript NO: 19768**

**Manuscript Type: Review**

**Elderly patient and inflammatory bowel disease**

Nimmons D *et al*. Inflammatory bowel disease in the elderly

**Danielle Nimmons, Jimmy K Limdi**

**Danielle Nimmons,**Inflammatory Bowel Diseases Section, the Pennine Acute Hospitals NHS Trust, Manchester BL97TD, United Kingdom

**Jimmy K Limdi,** Inflammatory Bowel Diseases Section, the Pennine Acute Hospitals NHS Trust, Manchester BL97TD, United Kingdom

**Jimmy K Limdi,** Institute of Inflammation and Repair, Manchester Academy of Health Sciences, University of Manchester, Manchester BL97TD, United Kingdom

**Jimmy K Limdi,** Institute of Inflammation Research, University of Manchester, Manchester BL97TD, United Kingdom

**Author contributions:** Nimmons D and Limdi JK wrote the paper.

**Conflict-of-interest statement:** Authors declare no conflict of interests for this article.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

**Correspondence to: Jimmy K Limdi, FRCP, FEBGH, AGAF, FACG, Consultant Gastroenterologist and Clinical Lead,** Inflammatory Bowel Diseases Section, the Pennine Acute Hospitals NHS Trust, Manchester BL97TD, United Kingdom. [jimmy.limdi@pat.nhs.uk](mailto:jimmy.limdi@pat.nhs.uk)

**Telephone:** +44-161-7782642

**Received:** May 20, 2015

**Peer-review started:** June 9, 2015

**First decision:** August 31, 2015

**Revised:** November 27, 2015

**Accepted:** December 13, 2015

**Article in press:**

**Published online:**

**Abstract**

The incidence and prevalence of inflammatory bowel disease (IBD) is increasing globally. Coupled with an ageing population, the number of older patients with IBD is set to increase. The clinical features and therapeutic options in young and elderly patients are comparable but there are some significant differences. The wide differential diagnosis of IBD in elderly patients may result in a delay in diagnosis. The relative dearth of data specific to elderly IBD patients often resulting from their exclusion from pivotal clinical trials and the lack of consensus guidelines have made clinical decisions somewhat challenging. In addition, age specific concerns such as co-morbidity; loco-motor and cognitive function, poly-pharmacy and its consequences need to be taken into account. In applying modern treatment paradigms to the elderly, the clinician must consider the potential for more pronounced adverse effects in this vulnerable group and set appropriate boundaries maximising benefit and minimising harm. Meanwhile, clinicians need to make personalised decisions but as evidence based as possible in the holistic, considered and optimal management of IBD in elderly patients. In this review we will cover the clinical features and therapeutic options of IBD in the elderly; as well as addressing common questions and challenges posed by its management.

**Key words**: Inflammatory bowel disease; Crohn’s disease; Ulcerative colitis; Elderly; Therapy; Clinical features

**© The Authors 2015**. Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** Inflammatory bowel disease can be mis-diagnosed as its clinical features are similar in younger and elderly patients. Therapeutic regimes are different with elderly patients being less likely to have immunosuppressant drugs and TNF’s. Important factors must also be considered when making clinical decisions, such as polypharmacy and co-morbidity. Finally, complications may be more common in the elderly. Further evidence through clinical trials and consensus guidelines are needed to assist clinicians in making evidence based decisions in these patients.

Nimmons D, Limdi JK. Elderly patient and inflammatory bowel disease. *World J Gastrointest Pharmacol Ther* 2015; In press

**INTRODUCTION**

The inflammatory bowel diseases (IBD) comprising Crohn’s disease (CD) and ulcerative colitis (UC) are idiopathic diseases of the gastrointestinal tract characterized by a relapsing and remitting course[1]. The incidence and prevalence of IBD is increasing worldwide[2,3]. An official consensus estimated the proportion of elderly people at 3%-17.8% of the population[4]. Individuals aged over 65 years represent the fastest growing age group and is expected to increase by 31% during this decade in the United States[5]. The rising global incidence of IBD, its negligible impact on mortality and an ageing population will all contribute to increasing numbers of “elderly” patients with IBD.

The challenges posed by clinical co-morbidity, poly-pharmacy and drug interactions, likely mismatch between chronological and biological age (functional status) and social issues underpin the complexities involved in the management of the elderly patient with IBD. No consensus guidelines currently exist to guide the management of this vulnerable group, often limited by heterogenous populations studied with differential definitions of endpoints and based on 8-52 wk duration studies, which are not truly reflective of a lifelong disease. Patients over 65 years are often excluded from therapeutic trials[6] and in some the median age of participants has been in the 30’s with few being elderly[7]. The paucity of clinical data compounded by the complexities in management emphasise the importance of an astute understanding of the available literature in compressing avoidable morbidity and achieving desired outcomes when treating elderly patients with IBD.

In this review we will address common questions and challenges posed by the management of elderly patients with IBD. As is widely accepted in the IBD literature, we have used age 60 years and above for this cohort of patients.

**EPIDEMIOLOGY OF ELDERLY IBD**

Although the peak incidence of IBD is between ages 20 to 39, a second peak is recognised between ages 50-70[8]. Individuals over the age of 60 contribute to 10%-15% of IBD diagnoses, compared to 5%-25% made in children or adolescents[8-11]. The incidence in the elderly decreases with increasing age, where 65% of patients are aged 60-70 years old, 25% aged 70-80 years and 10% are over 80 years[6]. Thus, it is important to recognise elderly patients with IBD as having either long-standing IBD or late-onset IBD, where a diagnosis is made at a later age.

The annual incidence of IBD is increasing world-wide although there is significant heterogeneity with some data coming from urban populations and others from large population-based registries[12]. Previous studies have also shown regional differences, with the incidence of CD and UC in the elderly being 4/100000 and 6-8/100000 respectively in the United States as compared to 8-10/100000 for UC and CD in Europe[13,14]. A large study investigating early-onset IBD from the EPIMAD registry in Northern France, suggests the percentage of late-onset IBD is on the rise at 5%-11%[15]. It is noteworthy that most epidemiological studies have been undertaken in Caucasian populations and in the “developed” world. Population ageing, however, is a global phenomenon and further epidemiological studies in the developing world including the elderly may help to unmask likely clues from the “exposome” in the aetiology of IBD[16].

**CLINICAL PRESENTATION OF IBD IN THE ELDERLY**

The clinical presentation is similar to that in younger individuals with some important differences (Table 1). The diagnosis may be delayed for reasons including access to specialist healthcare, disinclination to seek medical advice, an initial misdiagnosis compared to younger patients, and the higher prevalence of conditions mimicking IBD in the elderly[17]. Symptoms include weight loss, abdominal pain, anaemia and diarrhoea[17-19]. Elderly patients have a lower incidence of a family history of IBD and higher incidence of osteoporosis but the extent of extra-intestinal features is not significantly different to that in younger patients[17,18].

The diagnosis of CD may be delayed in older individuals with the mean time of diagnosis being 6.4 years compared to 2.4 years in younger people[17]. Elderly CD patients have more colonic involvement and inflammatory disease compared to younger patients with a lower frequency of fistula or strictures[17-21]. A change in disease behaviour is also less common in the elderly[21-23].

The first flare up of UC may be more severe[7,24-26]. However, the clinical presentation of UC may be subtle with less bleeding, diarrhoea and abdominal pain[25]. Distal disease (proctitis and left-sided colitis) is more common[21,25-27]. In a World Gastroenterology Organisation survey, proctitis was observed in 42% of UC patients aged over 60 years as compared to 33% in those under 60 years[24]. In the EPIMAD registry, 45% had left-sided colitis, 29% had proctitis and 26% had extensive colitis[15]. Furthermore, disease location tended to remain stable with only 16% of patients at follow-up having proximal disease extension[15]. Studies have suggested in UC that relapse is less likely in elderly patients but can be more severe [27-29]. The incidence of colectomy is higher in younger patients (1.9% *vs* 4.3% in older and younger patients)[21]. In the EPIMAD study only 16% of elderly onset UC had surgery 10 years after diagnosis[15].

Elderly patients tend to be hospitalised more often than younger patients. Ananthakrishnan and colleagues reported that 25% of all IBD-related hospital admissions in the United States were in patients aged over 65 years. These patients are more likely to be ill, more malnourished, anaemic and hypovolaemic with higher transfusion requirements, and longer post-operative hospital stay when they undergo surgery[30]. The majority of the healthcare spend associated with IBD relates to the cost of hospitalisation and surgery[30-32]. Increased age is an independent risk factor for hospital fatality in these patients[30,33-35]. The worse outcomes in hospitalised elderly IBD patients, higher mortality and economic impact from health resource utilization underpin the need for further prospective research into the natural history and well-designed clinical trials for therapy in this population.

Finally, thrombotic complications are more common in elderly IBD patients potentially driven by a combination of disease related hypercoagulability, reduced mobility and dehydration, all more common in the elderly[17,36]. In the Nationwide Inpatient Sample Cohort Study, the highest rates of venous thromboembolism were seen in elderly UC patients with a third aged 80 and above experiencing a venous clotting complication during hospitalization[30].

**DIFFERENTIAL DIAGNOSIS**

A wide range of conditions can mimic IBD often delaying a decisive diagnosis or leading to an erroneous diagnosis. Misdiagnosis may occur in up to 60% of elderly patients with IBD as compared to 15% of younger patients with a lag in diagnosis of up to 6 years[18]. Conditions commonly confused with IBD in this age group include complicated diverticular disease (diverticulitis and diverticular bleeding), ischaemic colitis, medication-associated diarrhoea (NSAIDs, antibiotics and others), infectious diarrhoea, radiation colopathy and microscopic colitis (Table 2).

Diverticular disease is present in 40%-60% of individuals aged 70 and above with diverticular bleeding being the most common complication to mimic IBD[37]. Abscess formation, perforation or indeed fistulisation may complicate differentiation between diverticultis and CD. Furthermore, diverticular colitis (also called segmental colitis associated with diverticula) can mirror distal colonic CD[38]. A recent Dutch study found that 8% of all IBD diagnoses had been inaccurate and were indeed segmental colitis associated with diverticular disease[39].

Radiation for gynaecological, or prostate cancers and NSAID-induced ulcers, strictures or perforation can mimic or complicate IBD[40,28]. Some studies have reported relapses in patients with IBD with non-selective NSAID use but not with selective COX II inhibitors[41].

Ischaemic colitis may also occur with segmental involvement causing particular confusion with CD. Abrupt onset of pain with bloody diarrhoea is suggestive of this diagnosis. Endoscopy, histopathology and in some instances imaging make it possible to differentiate it from CD[42]. Brandt *et al*[43] found that nearly 50% of their patients had been misdiagnosed with IBD and actually had ischaemic colitis.

Infectious colitis with bloody diarrhoea may often be confused with UC and a broad differential diagnosis must be considered, particularly Clostridium difficile infection (CDI), Shigella, Campylobacter, Salmonella and Escherichia coli 0157:H7. The acute onset of symptoms and associated fever is characteristic and the diagnosis is often made by stool culture with rapid symptom resolution within 1-2 wk. Infections causing chronic diarrhoea include Plesiomonas, Aeromonas and Yersinia. Yersinia causes terminal ileitis mimicking CD[44]. The rising incidence of CDI is of increasing concern, and is no longer regarded as a purely nosocomial infection but can also be community-acquired[45]. In older patients affected with a virulent strain this may have serious consequences with prolonged hospitalization, increased risk of surgery and greater mortality[45]. Specific risk factors for CDI in patients with IBD are colonic disease, corticosteroid therapy and the use of immunosuppressive drugs to control IBD[46]. Thus, CDI testing should be performed on all hospitalised patients with IBD, those experiencing a disease flare and those not responding to therapy[46].

**MEDICAL THERAPY**

***General considerations***

The principles of IBD treatment are the induction and maintenance of remission, prevent disease and treatment-related complications and improve quality of life. Important considerations in choosing a therapeutic agent include location and severity of inflammation, disease behaviour (inflammatory, stricturing or fistulising), the presence of extra-intestinal manifestations and other clinical co-morbidities. In that respect the therapy for IBD in the elderly is similar to that in younger patients but with some crucial considerations.

Elderly-onset IBD is usually not associated with disease progression[6,21-23]. Treatment paradigms have evolved often involving the use of highly potent immunosuppressive therapy (often in combination) earlier in the disease course in well selected patients, especially in CD[47,48]. The application of such treatment paradigms in the elderly, through extrapolation from clinical trial data must acknowledge important caveats discussed below.

Innate immune function declines with age. Ageing is associated with a reduction in Toll-like receptor 4-mediated pro-inflammatory cytokine production and mitogen-activated protein kinase expression[49-54]. Ageing also alters humoral immunity through decline in B cell precursors and consequent decline in immunoglobulins[55]. Malnutrition also accentuates decline in immune function[56,57].

Treatment of elderly IBD patients with immunosuppressive medication increases the risk of opportunistic infection and possibly even malignancy. The exclusion of patients older than 60 years from most therapeutic trials[6] and lack of drug efficacy trial data in older patients, coupled with a lack of clarity of appropriate clinical end points (objective *vs* symptom control) may limit evidence-based decision-making.

Polypharmacy is common in elderly patients with some studies showing that they may be on five medications on average and 25% regularly take more than six [58,59]. Thus, choice of drug therapy must take into account clinical co-morbidity, drug interactions and also the impact of polypharmacy on treatment adherence, which itself will impact on clinical outcomes[60] (Table 3). Age-related conditions, home circumstances, the influence of impaired mobility or memory and consequent need for practical support require astute clinical judgement.

***Aminosalicylates***

5-aminosalicylates are foundational therapy for the induction and maintenance of remission in UC[61]. Their role in CD is conflicting though patients with Crohn's colitis may benefit[62]. Despite this, in the EPIMAD study nearly 80% of patients with late-onset CD were prescribed a 5-ASA, possibly a reflection of physician hesitancy with immunosuppressive therapy[15].

In UC, combined therapy with oral and topical 5 – ASA is more effective than oral therapy alone[63,64]. Complex dosing regimens and polypharmacy may negatively influence compliance and once-daily dosing regimens may be preferable[65]. Adherence rates of 5-ASA’s are 40%-60% based on self-reporting and urinary drug measurements[66]. Anal sphincter incompetence ranges between 10 to 25% in hospitalised patients and 4% in outpatients[67]. Difficulties with the use of topical therapy may arise from physical limitations with reduced retention of enema fluid in the presence of active inflammation. Reduction in volume of the enema or substitution with a corticosteroid foam preparation may circumvent this problem.

5-Aminosalicylates are relatively safe and effective with reports of nephrotoxicity and interstitial nephritis being rare[61,68]. Interstitial nephritis, an idiosyncratic effect is unrelated to the duration or dose of 5-ASA. Common negative side effects include nausea, vomiting abdominal pain, headache and rash[64]. Paradoxical worsening of colitis can occur in just under 5% of patients, and improves after discontinuing the drug[69,70]. 5-Aminosalicylates can increase levels of the thiopurine metabolitie 6-thioguanine[71-73]; interact with isoniazid[58], and warfarin (particularly olsalazine) when an increase in international normalised ratio (INR) occurs[74,75].

***Antibiotics***

The role of antibiotics in the primary treatment of CD is debatable and may be used in some patients with mild – moderate colonic CD, infectious complications of fistulising CD, pouchitis and as an adjunct to surgical drainage of CD related abscesses[76]. They do not have an important role in UC, but have been used in the expectant management of fulminant colitis[77,78]. Metronidazole and ciprofloxacin are commonly used in IBD, often in combination.

Adverse effects of metronidazole include nausea, a metallic taste and neuropathy with longer use[74,79,80]. Inhibition of cytochrome P450 may lead to increased levels of HMG- CoA reductase inhibitors such as simvastatin, sildenafil and calcium channel blockers[80]. Metronidazole may affect warfarin thus prolonging the INR[14,75,80]. Patients should be advised to avoid alcohol due to the well-recognised Antabuse (disulfuram) like effect. The metabolism of metronidazole is increased when used with phenytoin. Concomitant use may increase the risk of lithium toxicity[80].

Ciprofloxacin decreases theophylline clearance and can cause central nervous system adverse effects including lowering of the seizure threshold; it may alter serum phenytoin levels and lead to an increased INR by increasing warfarin levels[81]. Elderly patients may be at particular risk of QT prolongation on ECG and Achilles tendon rupture[82]. The association of fluoroquinolones and Clostridium difficile colitis is of particular concern[83].

***Corticosteroids***

Corticosteroids are used to induce remission in UC with an inadequate response to 5-ASA, in acute severe UC and to induce but not maintain clinical remission in CD[84,85]. Elderly IBD patients with prolonged corticosteroid exposure are more likely to experience severe adverse events[86,87]. Dose related side effects were noted in 40% of elderly patients with long-term corticosteroid exposure and osteoporosis in 16% of patients[86]. Another study found osteoporotic-related fractures and osteonecrosis in 15% of elderly IBD patients[88]. Corticosteroids should be used in an appropriated manner in both dose and duration with careful contingency planning[89]. The wide prevalence of malabsorption and calcium and vitamin D deficiency in the elderly emphasise the importance of early and regular bone densitometry assessments. Bisphosphonates should be considered alongside vitamin D and calcium supplementation[90].

Other side effects of corticosteroids more pronounced in the elderly include altered mental state and depression[86,87], fluid retention, of particular significance in patients with underlying hypertension, congestive heart failure, diabetes and renal disease[86,87]. Older patients may also have ocular problems such as glaucoma, exacerbated by corticosteroids[86,87]. Corticosteroid clearance is decreased in the elderly[91]. The activity of drugs can be reduced, such as phenytoin, phenobarbital, ephedrine and rifampin due to an increase in corticosteroid metabolism[74]. Anticoagulant efficacy may also be affected and frequent checks of coagulation parameters is recommended[58].

Budesonide is recommended to induce remission in mild-to-moderate distal small bowel and right-sided colonic CD and affects bone metabolism less than conventional corticosteroids[91,92]. A novel formulation of Budesonide in a multi-matrix release formulation has been approved for use in mild-moderate extensive UC[92].

***Immune modulator therapy***

Immunomodulator therapy may be indicated in elderly patients with aminosalicylate resistance or corticosteroid dependence for the maintenance of remission. Thiopurines (Azathioprine and 6-Mercaptopurine) are useful in the preservation of remission in CD and UC whereas intramuscular methotrexate has efficacy in moderate to severe CD[64,93]. Although the efficacy of immune modifying agents in elderly and younger IBD patients appears similar, the literature is disparate with one study showing no differences in uptake[94], and another demonstrating immunosuppressive therapy use secondary to corticosteroid dependence[95]. In contrast, in a retrospective study of 393 IBD patients aged over 65 years, a third were on long-term corticosteroids (treatment duration over 6 mo) with only 6% on thiopurines (Azathioprine or 6-MP) and 1% on Methotrexate indicating underutilization[22].

Adverse events associated with thiopurine therapy include idiosyncratic reactions that develop in approximately 5% of patient and include: fever, pancreatitis and hepatitis[96]. Leucopenia may occur at any time during therapy and is determined mainly by activity of the enzyme thiopurine methyltransferase (TPMT), which metabolises azathioprine to its metabolite 6-thioguanine. TPMT deficiency can result in serious leucopenia and mandates vigilant monitoring of blood counts and chemistry particularly as the incidence of serious infection in the elderly is greater[96-99]. TPMT testing (enzyme activity or genetic) prior to initiation of thiopurine therapy can identify those at risk of serious myelosuppression[100,101]. TPMT deficiency is not the only mechanistic explanation for thiopurine-induced myelosuppression and vigilant blood count monitoring is mandated in all patients[102]. Thiopurines are also associated with an increased risk of non-melanoma skin cancer and patients should be counselled regarding appropriated exposure to sunshine with adequate precaution using barrier sun creams and an annual dermatological assessment[103].

Bone marrow toxicity can occur when thiopurines are used with allopurinol. In such instances, the thiopurine dose should be reduced to 25% of the standard dose[73,104,105]. Using both immunomodulators and allopurinol also increases infection incidence in the elderly[104,105]. The risk of leucopenia is also increased when thiopurines are used concomitantly with clotrimazole or angiotensin–converting enzyme inhibitors[104,105]. Thiopurine treatment increases the risk of non-Hodgkin's lymphoma, its duration, age and if used with TNF therapy[106-108]. The CESAME study identified older age, male sex and longer duration of disease as the main risk factors of developing lymphoma[108]. Of 23 patients diagnosed with incident lymphomas, 12 were aged 60 or above and the risk was further elevated in those on combined immunosuppressive therapy with thiopurine and Anti-TNF agents[108].

***Methotrexate***

Methotrexate is used in the treatment of CD but consensus opinion does not currently recommend its use in UC[109,110]. Although it has not been studied specifically in the elderly there is experience with its use in older patients with psoriasis and rheumatoid arthritis[111,112]. The efficacy is similar in younger and older patients although its metabolism through biliary and renal excretion may be affected by age[113].

NSAID’s may inhibit renal excretion, increasing toxicity[113]. Gastrointestinal and haematological toxicity are also more likely in older patients[113]. Common side-effects may include nausea, fatigue, rash and stomatitis but also using folic acid supplements can prevent or reduce these[114]. Other clinically relevant drug interactions include inhibition of methotrexate absorption by tetracycline and reduction in renal clearance by penicillin. Methotrexate alters theophylline clearance[14]. Loop diuretics and methotrexate can alter concentrations of either drug[115]. Methotrexate does not appear to increase the risk of lymphoma[116].

***Cyclosporine***

Cyclosporine is sometimes used as rescue therapy in fulminant colitis but with no definite superiority over infliximab its use in modern IBD therapy is likely to be limited[117]. Elderly patients are more likely to experience side effects[66,69,118,119]. Cyclosporine can interact with antibiotics, such as gentamicin and vancomycin, leading to increased nephrotoxicity; and NSAIDs, melphalan and histamine-2 receptor antagonists[74]. Cytochrome P450 inhibitors, such as verapamil and allopurinol, decrease the metabolism of cyclosporine and increase its serum levels[74]. Phenytoin, rifampin, carbamazepine and phenobarbital reduce cyclosporine blood levels via increased hepatic metabolism[74,120].

***Biological therapies***

The role of Anti-TNF therapy in the induction and maintenance of clinical and histological remission of moderate to severely active IBD has been established through pivotal trials with evidence that it reduces hospitalisation rates and surgery and improves quality of life[64,85]. There is a lack of data demonstrating how they affect older patients. Nonetheless, indications are similar to those for younger patients[121-123].

Data on anti-TNF therapy in the elderly however are conflicting with some studies demonstrating similar results in older and younger patients[123-125] and others showing them to be less effective in elderly patients[126,127]. One study from the Massachusetts General Hospital found a lower response in older patients (61%) as compared to 83% in younger Anti-TNF treated patients[127]. A recent Belgian study however reported similar clinical response rates[124].

In the EPIMAD study between 2.5%-10% of patients with elderly onset IBD received immunosuppressive agents after 1 year. Only 26 patients with CD and 4 with UC received Anti-TNF agents, which mirrors trends in other countries. This reflects relative underutilization of Anti-TNF therapy perhaps driven by physician concern with adverse effects[15].

Data on biologics safety in elderly patients are predominantly from the rheumatological literature and conflicting, with some studies showing no increased risk of infection and others showing a higher rate of discontinuation owing to adverse effects[128-130]. Early experience from the Mayo Clinic demonstrated 3 of 4 deaths due to infliximab treatment were in elderly patients. The independent contribution of age was unclear as these patients had a long disease course, more severe disease and co-morbidities[126]. Data from the Stockholm cohort study showed an increased risk of severe adverse effects and mortality in patients aged 60 years and above with severe infections occurring in 11% of elderly patients as compared to 2% in clinical trials and post marketing studies[121,131]. Notably, these patients were from a tertiary referral cohort and the control population in this study was retrospectively recruited which might lead one to speculate that patients treated with biologics may experience more serious disease and further complications[121]. Cottone and colleagues reported a 12% risk of serious infection when treated with biological therapy and 3% died from septic shock[125]. Desai and colleagues reported that 70% discontinued biological therapy after a mean of two years[127].

Biological therapy has been associated with risk of malignancy particularly lymphoma and melanoma skin cancer[132]. However, in most studies patients were prescribed concomitant immunosuppressant therapy and thus the risk of biological monotherapy is hard to extrapolate[116]. The TREAT registry, examining outcomes of CD treatment regimens in North America noted no increased risk of malignancy in patients treated with biologics as compared to other treatments. Furthermore, when compared to the background risk of other malignancies in the Surveillance, Epidemiology and End Results (SEER) database, no additional risk of malignancy was noted with biologics[62]. Long-term data are needed to define this risk.

Adverse effects relevant to clinical practice include exacerbation of congestive cardiac failure, psoriasis, infusion reactions and neurological sequelae such as demyelination[133,134]. The increase in mortality associated with exacerbation of congestive cardiac failure, a common comorbidity in the elderly population, contraindicates its use in the setting of NYHA class III and IV heart failure[135]. Taken together these data emphasise the need for an astute clinical judgement, assessment of disease severity and careful counselling of therapy related risks.

**SURGERY**

Failure of medical therapy is the most likely cause for elderly IBD patients to have surgery[21,136]. Surgery associated complications and mortality have decreased significantly over the years from 50% between 1960-1984 to 20% between 1994–1999[137]. Recent studies show that there is not much difference in the risk of surgery for older and younger IBD patients[21,138,139]. Ananthakrishnan and colleagues reported that although elderly UC patients were less likely to undergo surgery there were similar surgical rates amongst younger and older CD patients[136]. Factors attributable to adverse outcomes include advancing age, male gender and hypoalbuminemia and urgent surgery[22]. Clostridium difficile infection, colorectal cancer and dysplasia are more common indications for surgery in older patients.

Ileal pouch anal anastomosis (IPAA) is the surgical technique of choice in UC if the patient has good anal sphincter function and no history of faecal incontinence[84,140]. The American Society of Colon and Rectal Surgeons recommends that chronological age should not be an exclusion criterion for IPAA surgery[141]. Pouch function deteriorates with increasing age in all patients undergoing IPAA with faecal incontinence; this effect may be more pronounced in the elderly[142]. Despite this, patients report a high level of satisfaction with IPAA, with 89% of elderly UC patients stating that they would opt to undergo the procedure again and 96% willing to recommend it to others[143]. Careful patient selection taking anal sphincter function, loco-motor and cognitive function into account could lead to favourable outcomes.

**IBD RELATED COLORECTAL CANCER**

Colitis-associated colorectal cancer (CAC) is one of the most feared complications of long-standing UC and Crohn's colitis. Several risk factors are associated with the development of colorectal neoplasia and include disease extent and duration, severity of histologic and endoscopic inflammation, colitis associated dysplasia, family history and primary sclerosing cholangitis[64,144,145]. Patients with subtotal colitis and pancolitis have the highest risk of developing CAC whereas those with proctitis or distal proctosigmoiditis are at no increased risk compared to the general population[64,145,146]. Patients with left-sided disease (to splenic flexure) carry an intermediate risk but their risk approaches that of patients with pancolitis as disease duration increases[146,147]. The relative risk (RR) increases after 8 -10 years of disease and this forms a rationale behind the initiation of surveillance colonoscopy[64,144,145,148,149].

Surveillance guidelines for the elderly are not different but need a considered approach. Elderly patients with IBD must be considered in two groups: those diagnosed at a younger age, i.e. before the age of 60 (long-standing IBD) and those with onset of IBD at a later age (late-onset IBD); with long-standing IBD conferring a higher risk of CAC[64,144,145,148,149]. Shaukat and colleagues using a SEER-Medicare linkage program database recently demonstrated that patients transitioning to older age with CD or UC had an OR of 1.93 (*P* < 0.001) and 1.45 (*P* = 0.01) respectively, of developing CAC[150] thus reflecting disease duration, a risk factor for dysplasia in CAC. However, in a recent study comparing non-IBD patients over a six-year period, late-onset IBD was not associated with an increased risk of CAC[151]. This lower risk may be reflective of the shorter duration of the study although the immunobiology of CAC in older patients may be different.

The overriding principle governing colorectal cancer screening is that it should only be done in patients deemed fit to undergo colectomy should dysplasia be found and a life expectancy such that they would be expected to benefit[152]. Increasing age is an independent risk factor for complications at colonoscopy such as colonic perforation[153,154]. Careful patient selection and counselling is a key determinant to good outcomes[152].

**VACCINATIONS**

IBD patients treated with corticosteroids, immunomodulators and biological agents are at increased risk of developing infectious complications from immune suppression[155,156]. Elderly patients may have additional comorbidities and indeed immunosenescence makes them more susceptible to infection. Many of these diseases are vaccine preventable, yet there have been multiple case reports of infections including fulminant hepatitis and fatal varicella in IBD patients[157,158]. IBD patients are considered immunosuppressed with treatment if they are on 20 mg or more of prednisolone (or equivalent), on-going treatment with effective doses of thiopurines, methotrexate biological therapies or indeed have had these agents discontinued within 3 mo[155]. There are no significant differences in vaccination guidelines for elderly and younger IBD patients but patients over 60 years old may have sub-optimal serological responses[155,159,160]. Recommended vaccinations include the inactivated influenza vaccine annually, pneumococcal vaccine given periodically, the initial dose followed by the vaccination in over 65 years after five years whether immunosuppressed or not, the hepatitis B series of vaccinations (after immunity is checked and if not immune), the meningococcal vaccine in certain instances (living in enclosed spaces such as dormitories) and those who have undergone splenectomy[155,159]. Live vaccines should be avoided in immunosuppressed patients and these typically include the intranasal influenza, BCG, typhoid oral, varicella, yellow fever, anthrax, measles mumps and rubella (Table 4). If required, live vaccines must be given at least 3 wk before commencing meaningful immunosuppressive therapy or 3 mo after stopping such therapy. Inactivated vaccines may be given at any time from the diagnosis of IBD but ideally at the earliest available opportunity after diagnosis. Recent data suggest that administration of the live herpes zoster vaccine may be safe even in patients prescribed Anti-TNF agents[160]. The clinician must carefully weigh the pros and cons of vaccinating *vs* not vaccinating, as consensus guidelines do not currently recommend live vaccinations in patients on immunosuppressive therapy[158].

**FUNCTION, COGNITION AND QUALITY OF LIFE CONSIDERATIONS**

An appreciation of the potential differences between chronological and biological age is vital for the holistic management of an elderly patient with IBD. Thus, the distinction between “fit and frail” will facilitate a more considered approach[28]. A frail patient with co-morbid illnesses and limited mobility would be at a higher risk of a medical or surgical intervention than a “fit” elderly patient. Health care ultilisation by frail patients is notably higher and often related to multi-drug exposure, limited mobility, falls and cognitive impairment[161-167]. Data from the Nationwide Inpatient Sample showed worse outcomes from hospitalisations in elderly patients with 15.7% of patients aged 65-84 years and 35% of patients aged over 85 years requiring discharge to a nursing home or rehabilitation facility compared to less than 1% in individuals aged under 45 years. Furthermore, 12.6% of patients aged 65-84 years required home health care after discharge compared to 4.7% in those aged 18-45 years[136].

**CONCLUSION**

The rising global incidence of IBD and an ageing population implies that the prevalence of IBD in the elderly is set to increase. The clinical features and therapeutic options in elderly IBD patients are similar to those in younger patients but with important differences. The broad differential diagnosis and emerging patterns of phenotypic progression in the elderly, relative dearth of data specific to elderly IBD patients, their exclusion from pivotal clinical trials and the lack of consensus guidelines have made clinical decisions somewhat challenging. In addition, age specific concerns such as co-morbidity; loco-motor and cognitive function, poly-pharmacy and its consequences must all be taken into account. In applying modern treatment paradigms to the elderly, the clinician must pause to consider the potential for more pronounced adverse effects in this vulnerable group and set appropriate boundaries maximising benefit and minimising harm. There is an urgent need for more data on disease presentation and natural history, clinical trial data assessing treatment paradigms and medication safety, endoscopic complications and hospitalisation. Until then and as discussed, clinicians must make personalised decisions, as evidence based as possible in the holistic, considered and optimal management of elderly patients with IBD.

**REFERENCES**

|  |
| --- |
| 1. **Abraham C**, Cho JH. Inflammatory bowel disease. *N Engl J Med* 2009; **361**: 2066-2078 [PMID: 19923578 DOI: 10.1056/NEJMra0804647] 2. **Cosnes J**, Gower-Rousseau C, Seksik P, Cortot A. Epidemiology and natural history of inflammatory bowel diseases. *Gastroenterology* 2011; **140**: 1785-1794 [PMID: 21530745 DOI: 10.1053/j.gastro.2011.01.055] 3. **Molinié F**, Gower-Rousseau C, Yzet T, Merle V, Grandbastien B, Marti R, Lerebours E, Dupas JL, Colombel JF, Salomez JL, Cortot A. Opposite evolution in incidence of Crohn's disease and ulcerative colitis in Northern France (1988-1999). *Gut* 2004; **53**: 843-848 [PMID: 15138211 DOI: 10.1136/gut.2003.025346] 4. **Kinsella H**. An Aging World: 2008, International Population Reports. 2009. Available from: URL: http://www.census.gov/prod/2009pubs/p95-09-1.pdf 5. **Jennifer M**, Ortman VAV, Hogan and H. An Aging Nation: The Older Population in the United States Population Estimates and Projections. 2014. Available from: URL: https://www.census.gov/prod/2014pubs/p25-1140.pdf 6. **Charpentier C**, Salleron J, Savoye G, Fumery M, Merle V, Laberenne JE, Vasseur F, Dupas JL, Cortot A, Dauchet L, Peyrin-Biroulet L, Lerebours E, Colombel JF, Gower-Rousseau C. Natural history of elderly-onset inflammatory bowel disease: a population-based cohort study. *Gut* 2014; **63**: 423-432 [PMID: 23408350 DOI: 10.1136/gutjnl-2012-303864] 7. **Loftus EV**, Silverstein MD, Sandborn WJ, Tremaine WJ, Harmsen WS, Zinsmeister AR. Ulcerative colitis in Olmsted County, Minnesota, 1940-1993: incidence, prevalence, and survival. *Gut* 2000; **46**: 336-343 [PMID: 10673294 DOI: 10.1136/gut.46.3.336] 8. **Kelsen J**,Baldassano RN. Inflammatory bowel disease: the difference between children and adults. *Inflamm Bowel Dis* 2008; **14 Suppl 2**: S9-S11 [PMID: 18816756 DOI: 10.1097/00054725-200810001-00005] 9. **Travis S**. Is IBD different in the elderly? *Inflamm Bowel Dis* 2008; **14 Suppl 2**: S12-S13 [PMID: 18816682 DOI: 10.1002/ibd.20605] 10. **Bernstein CN**, Wajda A, Svenson LW, MacKenzie A, Koehoorn M, Jackson M, Fedorak R, Israel D, Blanchard JF. The epidemiology of inflammatory bowel disease in Canada: a population-based study. *Am J Gastroenterol* 2006; **101**: 1559-1568 [PMID: 16863561 DOI: 10.1111/j.1572-0241.2006.00603.x] 11. **Loftus EV**, Silverstein MD, Sandborn WJ, Tremaine WJ, Harmsen WS, Zinsmeister AR. Crohn's disease in Olmsted County, Minnesota, 1940-1993: incidence, prevalence, and survival. *Gastroenterology* 1998; **114**: 1161-1168 [PMID: 9609752 DOI: 10.1016/S0016-5085(98)70421-4] 12. **Molodecky NA**, Soon IS, Rabi DM, Ghali WA, Ferris M, Chernoff G, Benchimol EI, Panaccione R, Ghosh S, Barkema HW, Kaplan GG. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. *Gastroenterology* 2012; **142**: 46-54.e42; quiz e30 [PMID: 22001864 DOI: 10.1053/j.gastro.2011.10.001] 13. **Russel MG**, Stockbrügger RW. Epidemiology of inflammatory bowel disease: an update. *Scand J Gastroenterol* 1996; **31**: 417-427 [PMID: 8734336 DOI: 10.3109/00365529609006759] 14. **Greenwald DA**, Brandt LJ. Inflammatory Bowel Disease After Age 60. *Curr Treat Options Gastroenterol* 2003; **6**: 213-225 [PMID: 12744821 DOI: 10.1007/s11938-003-0003-z] 15. **Gower-Rousseau C**, Vasseur F, Fumery M, Savoye G, Salleron J, Dauchet L, Turck D, Cortot A, Peyrin-Biroulet L, Colombel JF. Epidemiology of inflammatory bowel diseases: new insights from a French population-based registry (EPIMAD). *Dig Liver Dis* 2013; **45**: 89-94 [PMID: 23107487 DOI: 10.1016/j.dld.2012.09.005] 16. **Wild CP**. Complementing the genome with an "exposome": the outstanding challenge of environmental exposure measurement in molecular epidemiology. *Cancer Epidemiol Biomarkers Prev* 2005; **14**: 1847-1850 [PMID: 16103423 DOI: 10.1158/1055-9965.EPI-05-0456] 17. **Harper PC**, McAuliffe TL, Beeken WL. Crohn's disease in the elderly. A statistical comparison with younger patients matched for sex and duration of disease. *Arch Intern Med* 1986; **146**: 753-755 [PMID: 3963958 DOI: 10.1001/archinte.1986.00360160189025] 18. **Wagtmans MJ**, Verspaget HW, Lamers CB, van Hogezand RA. Crohn's disease in the elderly: a comparison with young adults. *J Clin Gastroenterol* 1998; **27**: 129-133 [PMID: 9754773 DOI: 10.1097/00004836-199809000-00005] 19. **Greth J**, Török HP, Koenig A, Folwaczny C. Comparison of inflammatory bowel disease at younger and older age. *Eur J Med Res* 2004; **9**: 552-554 [PMID: 15689301] 20. **Polito JM**, Childs B, Mellits ED, Tokayer AZ, Harris ML, Bayless TM. Crohn's disease: influence of age at diagnosis on site and clinical type of disease. *Gastroenterology* 1996; **111**: 580-586 [PMID: 8780560 DOI: 10.1053/gast.1996.v111.pm8780560] 21. **Lakatos PL**, David G, Pandur T, Erdelyi Z, Mester G, Balogh M, Szipocs I, Molnar C, Komaromi E, Kiss LS, Lakatos L. IBD in the elderly population: results from a population-based study in Western Hungary, 1977-2008. *J Crohns Colitis* 2011; **5**: 5-13 [PMID: 21272797 DOI: 10.1016/j.crohns.2010.08.004] 22. **Juneja M**, Baidoo L, Schwartz MB, Barrie A, Regueiro M, Dunn M, Binion DG. Geriatric inflammatory bowel disease: phenotypic presentation, treatment patterns, nutritional status, outcomes, and comorbidity. *Dig Dis Sci* 2012; **57**: 2408-2415 [PMID: 22359191 DOI: 10.1007/s10620-012-2083-x] 23. **Quezada SM**, Steinberger EK, Cross RK. Association of age at diagnosis and Crohn's disease phenotype. *Age Ageing* 2013; **42**: 102-106 [PMID: 22918090 DOI: 10.1093/ageing/afs107] 24. **Softley A**, Myren J, Clamp SE, Bouchier IA, Watkinson G, de Dombal FT. Inflammatory bowel disease in the elderly patient. *Scand J Gastroenterol Suppl* 1988; **144**: 27-30 [PMID: 3165553] 25. **Riegler G**, Tartaglione MT, Carratú R, D'Incá R, Valpiani D, Russo MI, Papi C, Fiorentini MT, Ingrosso M, Andreoli A, Vecchi M. Age-related clinical severity at diagnosis in 1705 patients with ulcerative colitis: a study by GISC (Italian Colon-Rectum Study Group). *Dig Dis Sci* 2000; **45**: 462-465 [PMID: 10749318 DOI: 10.1023/A: 1005424603085] 26. **Zimmerman J**, Gavish D, Rachmilewitz D. Early and late onset ulcerative colitis: distinct clinical features. *J Clin Gastroenterol* 1985; **7**: 492-498 [PMID: 4086743 DOI: 10.1097/00004836-198512000-00010] 27. **del Val JH**. Old-age inflammatory bowel disease onset: a different problem? *World J Gastroenterol* 2011; **17**: 2734-2739 [PMID: 21734781 DOI: 10.3748/Wjg.V17.I22.2734] 28. **Katz S**, Pardi DS. Inflammatory bowel disease of the elderly: frequently asked questions (FAQs). *Am J Gastroenterol* 2011; **106**: 1889-1897 [PMID: 21862997 DOI: 10.1038/ajg.2011.271] 29. **Han SW**, McColl E, Barton JR, James P, Steen IN, Welfare MR. Predictors of quality of life in ulcerative colitis: the importance of symptoms and illness representations. *Inflamm Bowel Dis* 2005; **11**: 24-34 [PMID: 15674110 DOI: 10.1097/00054725-200501000-00004] 30. **Ananthakrishnan AN**, Binion DG. Treatment of ulcerative colitis in the elderly. *Dig Dis* 2009; **27**: 327-334 [PMID: 19786760 DOI: 10.1159/000228569] 31. **Bassi A**, Dodd S, Williamson P, Bodger K. Cost of illness of inflammatory bowel disease in the UK: a single centre retrospective study. *Gut* 2004; **53**: 1471-1478 [PMID: 15361497 DOI: 10.1136/gut.2004.041616] 32. **Odes S**, Vardi H, Friger M, Wolters F, Russel MG, Riis L, Munkholm P, Politi P, Tsianos E, Clofent J, Vermeire S, Monteiro E, Mouzas I, Fornaciari G, Sijbrandij J, Limonard C, Van Zeijl G, O'morain C, Moum B, Vatn M, Stockbrugger R. Cost analysis and cost determinants in a European inflammatory bowel disease inception cohort with 10 years of follow-up evaluation. *Gastroenterology* 2006; **131**: 719-728 [PMID: 16952541 DOI: 10.1053/j.gastro.2006.05.052] 33. **Loftus EV**. A matter of life or death: mortality in Crohn's disease. *Inflamm Bowel Dis* 2002; **8**: 428-429 [PMID: 12607512 DOI: 10.1097/00054725-200211000-00009] 34. **Wolters FL**, Russel MG, Sijbrandij J, Ambergen T, Odes S, Riis L, Langholz E, Politi P, Qasim A, Koutroubakis I, Tsianos E, Vermeire S, Freitas J, van Zeijl G, Hoie O, Bernklev T, Beltrami M, Rodriguez D, Stockbrügger RW, Moum B. Phenotype at diagnosis predicts recurrence rates in Crohn's disease. *Gut* 2006; **55**: 1124-1130 [PMID: 16361306 DOI: 10.1136/gut.2005.084061] 35. **Farrokhyar F**, Swarbrick ET, Irvine EJ. A critical review of epidemiological studies in inflammatory bowel disease. *Scand J Gastroenterol* 2001; **36**: 2-15 [PMID: 11218235 DOI: 10.1080/00365520150218002] 36. **Foxworthy DM**, Wilson JA. Crohn's disease in the elderly. Prolonged delay in diagnosis. *J Am Geriatr Soc* 1985; **33**: 492-495 [PMID: 4008848 DOI: 10.1111/j.1532-5415.1985.tb05462.x] 37. **Painter NS**, Burkitt DP. Diverticular disease of the colon: a deficiency disease of Western civilization. *Br Med J* 1971; **2**: 450-454 [PMID: 4930390 DOI: 10.1136/bmj.2.5759.450] 38. **Peppercorn MA**. Drug-responsive chronic segmental colitis associated with diverticula: a clinical syndrome in the elderly. *Am J Gastroenterol* 1992; **87**: 609-612 [PMID: 1595649] 39. **Hadithi M**, Cazemier M, Meijer GA, Bloemena E, Felt-Bersma RJ, Mulder CJ, Meuwissen SG, Pena AS, van Bodegraven AA. Retrospective analysis of old-age colitis in the Dutch inflammatory bowel disease population. *World J Gastroenterol* 2008; **14**: 3183-3187 [PMID: 18506923 DOI: 10.3748/wjg.14.3183] 40. **Faucheron JL**. Toxicity of non-steroidal anti-inflammatory drugs in the large bowel. *Eur J Gastroenterol Hepatol* 1999; **11**: 389-392 [PMID: 10321754 DOI: 10.1097/00042737-199904000-00005] 41. **Sandborn WJ**, Stenson WF, Brynskov J, Lorenz RG, Steidle GM, Robbins JL, Kent JD, Bloom BJ. Safety of celecoxib in patients with ulcerative colitis in remission: a randomized, placebo-controlled, pilot study. *Clin Gastroenterol Hepatol* 2006; **4**: 203-211 [PMID: 16469681 DOI: 10.1016/j.cgh.2005.12.002] 42. **Montoro MA**, Brandt LJ, Santolaria S, Gomollon F, Sánchez Puértolas B, Vera J, Bujanda L, Cosme A, Cabriada JL, Durán M, Mata L, Santamaría A, Ceña G, Blas JM, Ponce J, Ponce M, Rodrigo L, Ortiz J, Muñoz C, Arozena G, Ginard D, López-Serrano A, Castro M, Sans M, Campo R, Casalots A, Orive V, Loizate A, Titó L, Portabella E, Otazua P, Calvo M, Botella MT, Thomson C, Mundi JL, Quintero E, Nicolás D, Borda F, Martinez B, Gisbert JP, Chaparro M, Jimenez Bernadó A, Gómez-Camacho F, Cerezo A, Casal Nuñez E. Clinical patterns and outcomes of ischaemic colitis: results of the Working Group for the Study of Ischaemic Colitis in Spain (CIE study). *Scand J Gastroenterol* 2011; **46**: 236-246 [PMID: 20961178 DOI: 10.3109/00365521.2010.525794] 43. **Brandt L**, Boley S, Goldberg L, Mitsudo S, Berman A. Colitis in the elderly. A reappraisal. *Am J Gastroenterol* 1981; **76**: 239-245 [PMID: 7315820] 44. **Schumacher G**, Kollberg B, Sandstedt B. A prospective study of first attacks of inflammatory bowel disease and infectious colitis. Histologic course during the 1st year after presentation. *Scand J Gastroenterol* 1994; **29**: 318-332 [PMID: 8047806 DOI: 10.3109/00365529409094843] 45. **Pépin J**, Valiquette L, Cossette B. Mortality attributable to nosocomial Clostridium difficile-associated disease during an epidemic caused by a hypervirulent strain in Quebec. *CMAJ* 2005; **173**: 1037-1042 [PMID: 16179431 DOI: 10.1503/cmaj.050978] 46. **Cohen SH**, Gerding DN, Johnson S, Kelly CP, Loo VG, McDonald LC, Pepin J, Wilcox MH. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). *Infect Control Hosp Epidemiol* 2010; **31**: 431-455 [PMID: 20307191 DOI: 10.1086/651706] 47. **Colombel JF**, Sandborn WJ, Reinisch W, Mantzaris GJ, Kornbluth A, Rachmilewitz D, Lichtiger S, D'Haens G, Diamond RH, Broussard DL, Tang KL, van der Woude CJ, Rutgeerts P. Infliximab, azathioprine, or combination therapy for Crohn's disease. *N Engl J Med* 2010; **362**: 1383-1395 [PMID: 20393175 DOI: 10.1056/NEJMoa0904492] 48. **D'Haens G**, Baert F, van Assche G, Caenepeel P, Vergauwe P, Tuynman H, De Vos M, van Deventer S, Stitt L, Donner A, Vermeire S, Van de Mierop FJ, Coche JC, van der Woude J, Ochsenkühn T, van Bodegraven AA, Van Hootegem PP, Lambrecht GL, Mana F, Rutgeerts P, Feagan BG, Hommes D. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. *Lancet* 2008; **371**: 660-667 [PMID: 18295023 DOI: 10.1016/S0140-6736(08)60304-9] 49. **van Duin D**, Mohanty S, Thomas V, Ginter S, Montgomery RR, Fikrig E, Allore HG, Medzhitov R, Shaw AC. Age-associated defect in human TLR-1/2 function. *J Immunol* 2007; **178**: 970-975 [PMID: 17202359 DOI: 10.4049/jimmunol.178.2.970] 50. **Ogawa T**, Kitagawa M, Hirokawa K. Age-related changes of human bone marrow: a histometric estimation of proliferative cells, apoptotic cells, T cells, B cells and macrophages. *Mech Ageing Dev* 2000; **117**: 57-68 [PMID: 10958923 DOI: 10.1016/S0047-6374(00)00137-8] 51. **Plowden J**, Renshaw-Hoelscher M, Engleman C, Katz J, Sambhara S. Innate immunity in aging: impact on macrophage function. *Aging Cell* 2004; **3**: 161-167 [PMID: 15268749 DOI: 10.1111/j.1474-9728.2004.00102.x] 52. **Borrego F**, Alonso MC, Galiani MD, Carracedo J, Ramirez R, Ostos B, Peña J, Solana R. NK phenotypic markers and IL2 response in NK cells from elderly people. *Exp Gerontol* 1999; **34**: 253-265 [PMID: 10363791 DOI: 10.1016/S0531-5565(98)00076-X] 53. **Hayhoe RP**, Henson SM, Akbar AN, Palmer DB. Variation of human natural killer cell phenotypes with age: identification of a unique KLRG1-negative subset. *Hum Immunol* 2010; **71**: 676-681 [PMID: 20394788 DOI: 10.1016/j.humimm.2010.03.014] 54. **Jing Y**, Shaheen E, Drake RR, Chen N, Gravenstein S, Deng Y. Aging is associated with a numerical and functional decline in plasmacytoid dendritic cells, whereas myeloid dendritic cells are relatively unaltered in human peripheral blood. *Hum Immunol* 2009; **70**: 777-784 [PMID: 19596035 DOI: 10.1016/j.humimm.2009.07.005] 55. **Lazuardi L**, Jenewein B, Wolf AM, Pfister G, Tzankov A, Grubeck-Loebenstein B. Age-related loss of naïve T cells and dysregulation of T-cell/B-cell interactions in human lymph nodes. *Immunology* 2005; **114**: 37-43 [PMID: 15606793 DOI: 10.1111/j.1365-2567.2004.02006.x] 56. **Drey M**, Kaiser MJ. [Malnutrition in the elderly]. *Dtsch Med Wochenschr* 2011; **136**: 176-178 [PMID: 21271475 DOI: 10.1055/s-0031-1272503] 57. **Gavazzi G**, Krause KH. Ageing and infection. *Lancet Infect Dis* 2002; **2**: 659-666 [PMID: 12409046 DOI: 10.1016/S1473-3099(02)00437-1] 58. **Stallmach A**, Hagel S, Gharbi A, Settmacher U, Hartmann M, Schmidt C, Bruns T. Medical and surgical therapy of inflammatory bowel disease in the elderly - prospects and complications. *J Crohns Colitis* 2011; **5**: 177-188 [PMID: 21575879 DOI: 10.1016/j.crohns.2011.02.001] 59. **Cross RK**, Wilson KT, Binion DG. Polypharmacy and Crohn's disease. *Aliment Pharmacol Ther* 2005; **21**: 1211-1216 [PMID: 15882241 DOI: 10.1111/j.1365-2036.2005.02429.x] 60. **MacLaughlin EJ**, Raehl CL, Treadway AK, Sterling TL, Zoller DP, Bond CA. Assessing medication adherence in the elderly: which tools to use in clinical practice? *Drugs Aging* 2005; **22**: 231-255 [PMID: 15813656 DOI: 10.2165/00002512-200522030-00005] 61. **Muller AF**, Stevens PE, McIntyre AS, Ellison H, Logan RF. Experience of 5-aminosalicylate nephrotoxicity in the United Kingdom. *Aliment Pharmacol Ther* 2005; **21**: 1217-1224 [PMID: 15882242 DOI: 10.1111/j.1365-2036.2005.02462.x] 62. **Lichtenstein GR**, Feagan BG, Cohen RD, Salzberg BA, Diamond RH, Langholff W, Londhe A, Sandborn WJ. Drug therapies and the risk of malignancy in Crohn's disease: results from the TREAT™ Registry. *Am J Gastroenterol* 2014; **109**: 212-223 [PMID: 24394749 DOI: 10.1038/ajg.2013.441] 63. **Safdi M**, DeMicco M, Sninsky C, Banks P, Wruble L, Deren J, Koval G, Nichols T, Targan S, Fleishman C, Wiita B. A double-blind comparison of oral versus rectal mesalamine versus combination therapy in the treatment of distal ulcerative colitis. *Am J Gastroenterol* 1997; **92**: 1867-1871 [PMID: 9382054] 64. **Kornbluth A**, Sachar DB. Ulcerative colitis practice guidelines in adults: American College Of Gastroenterology, Practice Parameters Committee. *Am J Gastroenterol* 2010; **105**: 501-23; quiz 524 [PMID: 20068560 DOI: 10.1038/ajg.2009.727] 65. **Hussain SW**, Pardi DS. Inflammatory bowel disease in the elderly. *Drugs Aging* 2010; **27**: 617-624 [PMID: 20658790 DOI: 10.2165/11537340-000000000-00000] 66. **Kane SV**, Cohen RD, Aikens JE, Hanauer SB. Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis. *Am J Gastroenterol* 2001; **96**: 2929-2933 [PMID: 11693328 DOI: 10.1111/j.1572-0241.2001.04683.x] 67. **Rao SS**. Diagnosis and management of fecal incontinence. American College of Gastroenterology Practice Parameters Committee. *Am J Gastroenterol* 2004; **99**: 1585-1604 [PMID: 15307881 DOI: 10.1111/j.1572-0241.2004.40105.x] 68. **Gisbert JP**, González-Lama Y, Maté J. 5-Aminosalicylates and renal function in inflammatory bowel disease: a systematic review. *Inflamm Bowel Dis* 2007; **13**: 629-638 [PMID: 17243140 DOI: 10.1002/ibd.20099] 69. **Stein RB**, Hanauer SB. Comparative tolerability of treatments for inflammatory bowel disease. *Drug Saf* 2000; **23**: 429-448 [PMID: 11085348 DOI: 10.2165/00002018-200023050-00006] 70. **Kapur KC**, Williams GT, Allison MC. Mesalazine induced exacerbation of ulcerative colitis. *Gut* 1995; **37**: 838-839 [PMID: 8537058 DOI: 10.1136/gut.37.6.838] 71. **Lewis LD**, Benin A, Szumlanski CL, Otterness DM, Lennard L, Weinshilboum RM, Nierenberg DW. Olsalazine and 6-mercaptopurine-related bone marrow suppression: a possible drug-drug interaction. *Clin Pharmacol Ther* 1997; **62**: 464-475 [PMID: 9357398 DOI: 10.1016/S0009-9236(97)90125-9] 72. **de Boer NK**, Wong DR, Jharap B, de Graaf P, Hooymans PM, Mulder CJ, Rijmen F, Engels LG, van Bodegraven AA. Dose-dependent influence of 5-aminosalicylates on thiopurine metabolism. *Am J Gastroenterol* 2007; **102**: 2747-2753 [PMID: 17764493 DOI: 10.1111/j.1572-0241.2007.01511.x] 73. **Gisbert JP**, Gomollón F. Thiopurine-induced myelotoxicity in patients with inflammatory bowel disease: a review. *Am J Gastroenterol* 2008; **103**: 1783-1800 [PMID: 18557712 DOI: 10.1111/j.1572-0241.2008.01848.x] 74. **Greenwald DA**, Brandt LJ. Inflammatory Bowel Disease After Age 60. *Curr Treat Options Gastroenterol* 2003; **6**: 213-225 [PMID: 12744821 DOI: 10.1007/s11938-003-0003-z] 75. **Wells PS**, Holbrook AM, Crowther NR, Hirsh J. Interactions of warfarin with drugs and food. *Ann Intern Med* 1994; **121**: 676-683 [PMID: 7944078 DOI: 10.7326/0003-4819-121-9-199411010-00009] 76. **Khan KJ**, Ullman TA, Ford AC, Abreu MT, Abadir A, Marshall JK, Talley NJ, Moayyedi P. Antibiotic therapy in inflammatory bowel disease: a systematic review and meta-analysis. *Am J Gastroenterol* 2011; **106**: 661-673 [PMID: 21407187 DOI: 10.1038/ajg.2011.72] 77. **Mantzaris GJ**, Archavlis E, Christoforidis P, Kourtessas D, Amberiadis P, Florakis N, Petraki K, Spiliadi C, Triantafyllou G. A prospective randomized controlled trial of oral ciprofloxacin in acute ulcerative colitis. *Am J Gastroenterol* 1997; **92**: 454-456 [PMID: 9068468] 78. **Mantzaris GJ**, Hatzis A, Kontogiannis P, Triadaphyllou G. Intravenous tobramycin and metronidazole as an adjunct to corticosteroids in acute, severe ulcerative colitis. *Am J Gastroenterol* 1994; **89**: 43-46 [PMID: 8273796] 79. **Duffy LF**, Daum F, Fisher SE, Selman J, Vishnubhakat SM, Aiges HW, Markowitz JF, Silverberg M. Peripheral neuropathy in Crohn's disease patients treated with metronidazole. *Gastroenterology* 1985; **88**: 681-684 [PMID: 2981752] 80. **Freeman CD**, Klutman NE, Lamp KC. Metronidazole. A therapeutic review and update. *Drugs* 1997; **54**: 679-708 [PMID: 9360057 DOI: 10.2165/00003495-199754050-00003] 81. **Shakeri-Nejad K**, Stahlmann R. Drug interactions during therapy with three major groups of antimicrobial agents. *Expert Opin Pharmacother* 2006; **7**: 639-651 [PMID: 16556082 DOI: 10.1517/14656566.7.6.639] 82. **Yu C**, Giuffre B. Achilles tendinopathy after treatment with fluoroquinolone. *Australas Radiol* 2005; **49**: 407-410 [PMID: 16174181 DOI: 10.1111/j.1440-1673.2005.01470.x] 83. **Louie TJ**, Miller MA, Crook DW, Lentnek A, Bernard L, High KP, Shue YK, Gorbach SL. Effect of age on treatment outcomes in Clostridium difficile infection. *J Am Geriatr Soc* 2013; **61**: 222-230 [PMID: 23379974 DOI: 10.1111/jgs.12090] 84. **Dignass A**, Lindsay JO, Sturm A, Windsor A, Colombel JF, Allez M, D'Haens G, D'Hoore A, Mantzaris G, Novacek G, Oresland T, Reinisch W, Sans M, Stange E, Vermeire S, Travis S, Van Assche G. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management. *J Crohns Colitis* 2012; **6**: 991-1030 [PMID: 23040451 DOI: 10.1016/j.crohns.2012.09.002] 85. **Lichtenstein GR**, Hanauer SB, Sandborn WJ. Management of Crohn's disease in adults. *Am J Gastroenterol* 2009; **104**: 465-83; quiz 464, 484 [PMID: 19174807 DOI: 10.1038/ajg.2008.168] 86. **Thomas TP**. The complications of systemic corticosteroid therapy in the elderly. A retrospective study. *Gerontology* 1984; **30**: 60-65 [PMID: 6698408] 87. **Akerkar GA**, Peppercorn MA, Hamel MB, Parker RA. Corticosteroid-associated complications in elderly Crohn's disease patients. *Am J Gastroenterol* 1997; **92**: 461-464 [PMID: 9068470] 88. **Tilg H**, Moschen AR, Kaser A, Pines A, Dotan I. Gut, inflammation and osteoporosis: basic and clinical concepts. *Gut* 2008; **57**: 684-694 [PMID: 18408105 DOI: 10.1136/gut.2006.117382] 89. **Lichtenstein GR**, Sands BE, Pazianas M. Prevention and treatment of osteoporosis in inflammatory bowel disease. *Inflamm Bowel Dis* 2006; **12**: 797-813 [PMID: 16917235 DOI: 10.1097/00054725-200608000-00016] 90. **Swaroop PP**. Inflammatory bowel diseases in the elderly. *Clin Geriatr Med* 2007; **23**: 809-21, vi [PMID: 17923339 DOI: 10.1016/j.cger.2007.06.007] 91. **Frey BM**, Frey FJ. Clinical pharmacokinetics of prednisone and prednisolone. *Clin Pharmacokinet* 1990; **19**: 126-146 [PMID: 2199128 DOI: 10.2165/00003088-199019020-00003] 92. **Travis SP**, Danese S, Kupcinskas L, Alexeeva O, D'Haens G, Gibson PR, Moro L, Jones R, Ballard ED, Masure J, Rossini M, Sandborn WJ. Once-daily budesonide MMX in active, mild-to-moderate ulcerative colitis: results from the randomised CORE II study. *Gut* 2014; **63**: 433-441 [PMID: 23436336 DOI: 10.1136/gutjnl-2012-304258] 93. **Feagan BG**, Rochon J, Fedorak RN, Irvine EJ, Wild G, Sutherland L, Steinhart AH, Greenberg GR, Gillies R, Hopkins M. Methotrexate for the treatment of Crohn's disease. The North American Crohn's Study Group Investigators. *N Engl J Med* 1995; **332**: 292-297 [PMID: 7816064 DOI: 10.1056/NEJM199502023320503] 94. **Matsumoto S**, Miyatani H, Yoshida Y. Ulcerative colitis: comparison between elderly and young adult patients and between elderly patients with late-onset and long-standing disease. *Dig Dis Sci* 2013; **58**: 1306-1312 [PMID: 23306844 DOI: 10.1007/s10620-012-2517-5] 95. **Rodríguez-D'Jesus A**, Casellas F, Malagelada JR. [Epidemiology of inflammatory bowel disease in the elderly]. *Gastroenterol Hepatol* 2008; **31**: 269-273 [PMID: 18448054 DOI: 10.1157/13119877] 96. **Present DH**, Meltzer SJ, Krumholz MP, Wolke A, Korelitz BI. 6-Mercaptopurine in the management of inflammatory bowel disease: short- and long-term toxicity. *Ann Intern Med* 1989; **111**: 641-649 [PMID: 2802419 DOI: 10.7326/0003-4819-111-8-641] 97. **Weinshilboum RM**, Sladek SL. Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. *Am J Hum Genet* 1980; **32**: 651-662 [PMID: 7191632] 98. **Connell WR**, Kamm MA, Ritchie JK, Lennard-Jones JE. Bone marrow toxicity caused by azathioprine in inflammatory bowel disease: 27 years of experience. *Gut* 1993; **34**: 1081-1085 [PMID: 8174958 DOI: 10.1136/gut.34.8.1081] 99. **Bouhnik Y**, Lémann M, Mary JY, Scemama G, Taï R, Matuchansky C, Modigliani R, Rambaud JC. Long-term follow-up of patients with Crohn's disease treated with azathioprine or 6-mercaptopurine. *Lancet* 1996; **347**: 215-219 [PMID: 8551879 DOI: 10.1016/S0140-6736(96)90402-X] 100. **Black AJ**, McLeod HL, Capell HA, Powrie RH, Matowe LK, Pritchard SC, Collie-Duguid ES, Reid DM. Thiopurine methyltransferase genotype predicts therapy-limiting severe toxicity from azathioprine. *Ann Intern Med* 1998; **129**: 716-718 [PMID: 9841604 DOI: 10.7326/0003-4819-129-9-199811010-00007] 101. **Cuffari C**, Dassopoulos T, Turnbough L, Thompson RE, Bayless TM. Thiopurine methyltransferase activity influences clinical response to azathioprine in inflammatory bowel disease. *Clin Gastroenterol Hepatol* 2004; **2**: 410-417 [PMID: 15118980 DOI: 10.1016/S1542-3565(04)00127-2] 102. **Chaparro M**, Ordás I, Cabré E, Garcia-Sanchez V, Bastida G, Peñalva M, Gomollón F, García-Planella E, Merino O, Gutiérrez A, Esteve M, Márquez L, Garcia-Sepulcre M, Hinojosa J, Vera I, Muñoz F, Mendoza JL, Cabriada JL, Montoro MA, Barreiro-de Acosta M, Ceña G, Saro C, Aldeguer X, Barrio J, Maté J, Gisbert JP. Safety of thiopurine therapy in inflammatory bowel disease: long-term follow-up study of 3931 patients. *Inflamm Bowel Dis* 2013; **19**: 1404-1410 [PMID: 23665964 DOI: 10.1097/MIB.0b013e318281f28f] 103. **Ariyaratnam J**, Subramanian V. Association between thiopurine use and nonmelanoma skin cancers in patients with inflammatory bowel disease: a meta-analysis. *Am J Gastroenterol* 2014; **109**: 163-169 [PMID: 24419479 DOI: 10.1038/ajg.2013.451] 104. **Govani SM**, Higgins PD. Combination of thiopurines and allopurinol: adverse events and clinical benefit in IBD. *J Crohns Colitis* 2010; **4**: 444-449 [PMID: 21122542 DOI: 10.1016/j.crohns.2010.02.009] 105. **Sparrow MP**, Hande SA, Friedman S, Cao D, Hanauer SB. Effect of allopurinol on clinical outcomes in inflammatory bowel disease nonresponders to azathioprine or 6-mercaptopurine. *Clin Gastroenterol Hepatol* 2007; **5**: 209-214 [PMID: 17296529 DOI: 10.1016/j.cgh.2006.11.020] 106. **Siegel CA**, Marden SM, Persing SM, Larson RJ, Sands BE. Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease: a meta-analysis. *Clin Gastroenterol Hepatol* 2009; **7**: 874-881 [PMID: 19558997 DOI: 10.1016/j.cgh.2009.01.004] 107. **Khan N**, Abbas AM, Lichtenstein GR, Loftus EV, Bazzano LA. Risk of lymphoma in patients with ulcerative colitis treated with thiopurines: a nationwide retrospective cohort study. *Gastroenterology* 2013; **145**: 1007-1015.e3 [PMID: 23891975 DOI: 10.1053/j.gastro.2013.07.035] 108. **Beaugerie L**, Brousse N, Bouvier AM, Colombel JF, Lémann M, Cosnes J, Hébuterne X, Cortot A, Bouhnik Y, Gendre JP, Simon T, Maynadié M, Hermine O, Faivre J, Carrat F. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. *Lancet* 2009; **374**: 1617-1625 [PMID: 19837455 DOI: 10.1016/S0140-6736(09)61302-7] 109. **Patel V**, Wang Y, MacDonald JK, McDonald JW, Chande N. Methotrexate for maintenance of remission in Crohn's disease. *Cochrane Database Syst Rev* 2014; **8**: CD006884 [PMID: 25157445 DOI: 10.1002/14651858.cd006884.pub3] 110. **Chande N**, Wang Y, MacDonald JK, McDonald JW. Methotrexate for induction of remission in ulcerative colitis. *Cochrane Database Syst Rev* 2014; **8**: CD006618 [PMID: 25162749 DOI: 10.1002/14651858.cd006618.pub3] 111. **Busard C**, Zweegers J, Limpens J, Langendam M, Spuls PI. Combined use of systemic agents for psoriasis: a systematic review. *JAMA Dermatol* 2014; **150**: 1213-1220 [PMID: 25188393 DOI: 10.1001/jamadermatol.2014.1111] 112. **Buttgereit F**, Smolen JS, Coogan AN, Cajochen C. Clocking in: chronobiology in rheumatoid arthritis. *Nat Rev Rheumatol* 2015; **11**: 349-356 [PMID: 25800214 DOI: 10.1038/nrrheum.2015.31] 113. **Morgacheva O**, Furst DE. Use of MTX in the elderly and in patients with compromised renal function. *Clin Exp Rheumatol* ; **28**: S85-S94 [PMID: 21044439] 114. **Shea B**, Swinden MV, Ghogomu ET, Ortiz Z, Katchamart W, Rader T, Bombardier C, Wells GA, Tugwell P. Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis. *J Rheumatol* 2014; **41**: 1049-1060 [PMID: 24737913 DOI: 10.3899/jrheum.130738] 115. **Bourré-Tessier J**, Haraoui B. Methotrexate drug interactions in the treatment of rheumatoid arthritis: a systematic review. *J Rheumatol* 2010; **37**: 1416-1421 [PMID: 20436072 DOI: 10.3899/jrheum.090153] 116. **Subramaniam K**, D'Rozario J, Pavli P. Lymphoma and other lymphoproliferative disorders in inflammatory bowel disease: a review. *J Gastroenterol Hepatol* 2013; **28**: 24-30 [PMID: 23094824 DOI: 10.1111/jgh.12015] 117. **Laharie D**, Bourreille A, Branche J, Allez M, Bouhnik Y, Filippi J, Zerbib F, Savoye G, Nachury M, Moreau J, Delchier JC, Cosnes J, Ricart E, Dewit O, Lopez-Sanroman A, Dupas JL, Carbonnel F, Bommelaer G, Coffin B, Roblin X, Van Assche G, Esteve M, Färkkilä M, Gisbert JP, Marteau P, Nahon S, de Vos M, Franchimont D, Mary JY, Colombel JF, Lémann M. Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial. *Lancet* 2012; **380**: 1909-1915 [PMID: 23063316 DOI: 10.1016/S0140-6736(12)61084-8] 118. **Gisbert JP**, Chaparro M. Systematic review with meta-analysis: inflammatory bowel disease in the elderly. *Aliment Pharmacol Ther* 2014; **39**: 459-477 [PMID: 24405149 DOI: 10.1111/apt.12616] 119. **Kovarik JM**, Koelle EU. Cyclosporin pharmacokinetics in the elderly. *Drugs Aging* 1999; **15**: 197-205 [PMID: 10503812 DOI: 10.2165/00002512-199915030-00003] 120. **Dunn CJ**, Wagstaff AJ, Perry CM, Plosker GL, Goa KL. Cyclosporin: an updated review of the pharmacokinetic properties, clinical efficacy and tolerability of a microemulsion-based formulation (neoral)1 in organ transplantation. *Drugs* 2001; **61**: 1957-2016 [PMID: 11708766 DOI: 10.2165/00003495-200161130-00006] 121. **Ljung T**, Karlén P, Schmidt D, Hellström PM, Lapidus A, Janczewska I, Sjöqvist U, Löfberg R. Infliximab in inflammatory bowel disease: clinical outcome in a population based cohort from Stockholm County. *Gut* 2004; **53**: 849-853 [PMID: 15138212 DOI: 10.1136/gut.2003.018515] 122. **Seiderer J**, Göke B, Ochsenkühn T. Safety aspects of infliximab in inflammatory bowel disease patients. A retrospective cohort study in 100 patients of a German University Hospital. *Digestion* 2004; **70**: 3-9 [PMID: 15297773 DOI: 10.1159/000080075] 123. **Chevillotte-Maillard H**, Ornetti P, Mistrih R, Sidot C, Dupuis J, Dellas JA, Tavernier C, Maillefert JF. Survival and safety of treatment with infliximab in the elderly population. *Rheumatology (Oxford)* 2005; **44**: 695-696 [PMID: 15705631 DOI: 10.1093/rheumatology/keh562] 124. **Lobatón T**, Ferrante M, Rutgeerts P, Ballet V, Van Assche G, Vermeire S. Efficacy and safety of anti-TNF therapy in elderly patients with inflammatory bowel disease. *Aliment Pharmacol Ther* 2015; **42**: 441-451 [PMID: 26104047 DOI: 10.1111/apt.13294] 125. **Cottone M**, Kohn A, Daperno M, Armuzzi A, Guidi L, D'Inca R, Bossa F, Angelucci E, Biancone L, Gionchetti P, Ardizzone S, Papi C, Fries W, Danese S, Riegler G, Cappello M, Castiglione F, Annese V, Orlando A. Advanced age is an independent risk factor for severe infections and mortality in patients given anti-tumor necrosis factor therapy for inflammatory bowel disease. *Clin Gastroenterol Hepatol* 2011; **9**: 30-35 [PMID: 20951835 DOI: 10.1016/j.cgh.2010.09.026] 126. **Colombel JF**, Loftus EV, Tremaine WJ, Egan LJ, Harmsen WS, Schleck CD, Zinsmeister AR, Sandborn WJ. The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients. *Gastroenterology* 2004; **126**: 19-31 [PMID: 14699483 DOI: 10.1053/j.gastro.2003.10.047] 127. **Desai A**, Zator ZA, de Silva P, Nguyen DD, Korzenik J, Yajnik V, Ananthakrishnan AN. Older age is associated with higher rate of discontinuation of anti-TNF therapy in patients with inflammatory bowel disease. *Inflamm Bowel Dis* 2013; **19**: 309-315 [PMID: 22605668 DOI: 10.1002/ibd.23026] 128. **Schneeweiss S**, Setoguchi S, Weinblatt ME, Katz JN, Avorn J, Sax PE, Levin R, Solomon DH. Anti-tumor necrosis factor alpha therapy and the risk of serious bacterial infections in elderly patients with rheumatoid arthritis. *Arthritis Rheum* 2007; **56**: 1754-1764 [PMID: 17530704 DOI: 10.1002/art.22600] 129. **Marchesoni A**, Zaccara E, Gorla R, Bazzani C, Sarzi-Puttini P, Atzeni F, Caporali R, Bobbio-Pallavicini F, Favalli EG. TNF-alpha antagonist survival rate in a cohort of rheumatoid arthritis patients observed under conditions of standard clinical practice. *Ann N Y Acad Sci* 2009; **1173**: 837-846 [PMID: 19758236 DOI: 10.1111/j.1749-6632.2009.04621.x] 130. **Filippini M**, Bazzani C, Favalli EG, Marchesoni A, Atzeni F, Sarzi-Puttini P, Pallavicini FB, Caporali R, Gorla R. Efficacy and safety of anti-tumour necrosis factor in elderly patients with rheumatoid arthritis: an observational study. *Clin Rev Allergy Immunol* 2010; **38**: 90-96 [PMID: 19548124 DOI: 10.1007/s12016-009-8142-1] 131. **Lichtenstein GR**, Feagan BG, Cohen RD, Salzberg BA, Diamond RH, Chen DM, Pritchard ML, Sandborn WJ. Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. *Clin Gastroenterol Hepatol* 2006; **4**: 621-630 [PMID: 16678077 DOI: 10.1016/j.cgh.2006.03.002] 132. **Long MD**, Martin CF, Pipkin CA, Herfarth HH, Sandler RS, Kappelman MD. Risk of melanoma and nonmelanoma skin cancer among patients with inflammatory bowel disease. *Gastroenterology* 2012; **143**: 390-399.e1 [PMID: 22584081 DOI: 10.1053/j.gastro.2012.05.004] 133. **O'Meara S**, Nanda KS, Moss AC. Antibodies to infliximab and risk of infusion reactions in patients with inflammatory bowel disease: a systematic review and meta-analysis. *Inflamm Bowel Dis* 2014; **20**: 1-6 [PMID: 24280879 DOI: 10.1097/01.MIB.0000436951.80898.6d] 134. **Denadai R**, Teixeira FV, Saad-Hossne R. Management of psoriatic lesions associated with anti-TNF therapy in patients with IBD. *Nat Rev Gastroenterol Hepatol* 2012; **9**: 744 [PMID: 23147656 DOI: 10.1038/nrgastro.2012.125-c1] 135. **Singh JA**, Wells GA, Christensen R, Tanjong Ghogomu E, Maxwell L, Macdonald JK, Filippini G, Skoetz N, Francis D, Lopes LC, Guyatt GH, Schmitt J, La Mantia L, Weberschock T, Roos JF, Siebert H, Hershan S, Lunn MP, Tugwell P, Buchbinder R. Adverse effects of biologics: a network meta-analysis and Cochrane overview. *Cochrane Database Syst Rev* 2011; : CD008794 [PMID: 21328309 DOI: 10.1002/14651858.cd008794.pub2] 136. **Ananthakrishnan AN**, McGinley EL, Binion DG. Inflammatory bowel disease in the elderly is associated with worse outcomes: a national study of hospitalizations. *Inflamm Bowel Dis* 2009; **15**: 182-189 [PMID: 18668678 DOI: 10.1002/ibd.20628] 137. **Almogy G**, Sachar DB, Bodian CA, Greenstein AJ. Surgery for ulcerative colitis in elderly persons: changes in indications for surgery and outcome over time. *Arch Surg* 2001; **136**: 1396-1400 [PMID: 11735867 DOI: 10.1001/archsurg.136.12.1396] 138. **Jeuring S**, Van den Heuvel T, Zeegers M, Hameeteman W, Romberg-Camps M, Oostenbrug L, Masclee A, Jonkers D, Pierik M. OP005 Is elderly-onset ulcerative colitis a different entity? – Natural disease course and treatment response compared to adult-onset disease in the population-based IBD-SL cohort. *J Crohn's Colitis* 2014; **8 Suppl 1**: S3–S4 [DOI: [10.1016/S1873-9946(14)60006-4](http://dx.doi.org/10.1016/S1873-9946(14)60006-4)] 139. **Fries W**, Viola A, Mannetti N, Coppola M, Frankovic I, Monterubbianesi R, Cantoro L, Pugliese D, Aratri A, Cappello M, Saibeni S, Principi M, Naccarato P, Mocci G, Castiglione F, Callela F, Magarotto A, Caprioli F, Belvedere A, Casella G, Samperi L, Privitera AC, Inserra G, Danese S, Papi C, Armuzzi A, Kohn A, D'Incà R, Annese V, Manguso F. P303 Ulcerative colitis (UC) in the elderly – Moderate at onset but then a milder course? An IG-IBD study. *J Crohn's Colitis* 2014; **8 Suppl 1**: S190–S191 [DOI: 10.1016/S1873-9946(14)60424-4] 140. **Delaney CP**, Fazio VW, Remzi FH, Hammel J, Church JM, Hull TL, Senagore AJ, Strong SA, Lavery IC. Prospective, age-related analysis of surgical results, functional outcome, and quality of life after ileal pouch-anal anastomosis. *Ann Surg* 2003; **238**: 221-228 [PMID: 12894015 DOI: 10.1097/01.sla.0000080825.95166.26] 141. **Cohen JL**, Strong SA, Hyman NH, Buie WD, Dunn GD, Ko CY, Fleshner PR, Stahl TJ, Kim DG, Bastawrous AL, Perry WB, Cataldo PA, Rafferty JF, Ellis CN, Rakinic J, Gregorcyk S, Shellito PC, Kilkenny JW, Ternent CA, Koltun W, Tjandra JJ, Orsay CP, Whiteford MH, Penzer JR. Practice parameters for the surgical treatment of ulcerative colitis. *Dis Colon Rectum* 2005; **48**: 1997-2009 [PMID: 16258712 DOI: 10.1007/s10350-005-0180-z] 142. **Church JM**. Functional outcome and quality of life in an elderly patient with an ileal pouch-anal anastomosis: a 10-year follow up. *Aust N Z J Surg* 2000; **70**: 906-907 [PMID: 11167585 DOI: 10.1046/j.1440-1622.2000.02006.x] 143. **Delaney CP**, Dadvand B, Remzi FH, Church JM, Fazio VW. Functional outcome, quality of life, and complications after ileal pouch-anal anastomosis in selected septuagenarians. *Dis Colon Rectum* 2002; **45**: 890-84; discussion 894 [PMID: 12130876 DOI: 10.1007/s10350-004-6323-9] 144. **Cairns SR**, Scholefield JH, Steele RJ, Dunlop MG, Thomas HJ, Evans GD, Eaden JA, Rutter MD, Atkin WP, Saunders BP, Lucassen A, Jenkins P, Fairclough PD, Woodhouse CR. Guidelines for colorectal cancer screening and surveillance in moderate and high risk groups (update from 2002). *Gut* 2010; **59**: 666-689 [PMID: 20427401 DOI: 10.1136/gut.2009.179804] 145. **Farraye FA**, Odze RD, Eaden J, Itzkowitz SH, McCabe RP, Dassopoulos T, Lewis JD, Ullman TA, James T, McLeod R, Burgart LJ, Allen J, Brill JV. AGA medical position statement on the diagnosis and management of colorectal neoplasia in inflammatory bowel disease. *Gastroenterology* 2010; **138**: 738-745 [PMID: 20141808 DOI: 10.1053/j.gastro.2009.12.037] 146. **Ekbom A**, Helmick C, Zack M, Adami HO. Ulcerative colitis and colorectal cancer. A population-based study. *N Engl J Med* 1990; **323**: 1228-1233 [PMID: 2215606 DOI: 10.1056/NEJM199011013231802] 147. **Sugita A**, Sachar DB, Bodian C, Ribeiro MB, Aufses AH, Greenstein AJ. Colorectal cancer in ulcerative colitis. Influence of anatomical extent and age at onset on colitis-cancer interval. *Gut* 1991; **32**: 167-169 [PMID: 1864536 DOI: 10.1136/gut.32.2.167] 148. **Eaden JA**, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. *Gut* 2001; **48**: 526-535 [PMID: 11247898 DOI: 10.1136/gut.48.4.526] 149. **Rutter MD**, Saunders BP, Wilkinson KH, Rumbles S, Schofield G, Kamm MA, Williams CB, Price AB, Talbot IC, Forbes A. Thirty-year analysis of a colonoscopic surveillance program for neoplasia in ulcerative colitis. *Gastroenterology* 2006; **130**: 1030-1038 [PMID: 16618396 DOI: 10.1053/j.gastro.2005.12.035] 150. **Shaukat A**, Virnig DJ, Salfiti NI, Howard DH, Sitaraman SV, Liff JM. Is inflammatory bowel disease an important risk factor among older persons with colorectal cancer in the United States? A population-based case-control study. *Dig Dis Sci* 2011; **56**: 2378-2383 [PMID: 21409378 DOI: 10.1007/s10620-011-1632-z] 151. **Cheddani H**, Dauchet L, Charpentier C, Fumery M, Salleron J, Bouvier A-M, Dupas JL, Vasseur F, Lerebours E, Armengol-Debeir L, Laberenne E, Peyrin-Biroulet L, Colombel J-F, Savoye G, Gower-Rousseau C. DOP094 Cancer in elderly-onset inflammatory bowel disease: A population-based study. *J Crohn's Colitis* 2014; **8 Suppl 1**: S60 [DOI: 10.1016/S1873-9946(14)60119-7] 152. **Rex DK**, Johnson DA, Anderson JC, Schoenfeld PS, Burke CA, Inadomi JM. American College of Gastroenterology guidelines for colorectal cancer screening 2009 [corrected]. *Am J Gastroenterol* 2009; **104**: 739-750 [PMID: 19240699 DOI: 10.1038/ajg.2009.104] 153. **Bielawska B**, Day AG, Lieberman DA, Hookey LC. Risk factors for early colonoscopic perforation include non-gastroenterologist endoscopists: a multivariable analysis. *Clin Gastroenterol Hepatol* 2014; **12**: 85-92 [PMID: 23891916 DOI: 10.1016/j.cgh.2013.06.030] 154. **Navaneethan U**, Parasa S, Venkatesh PG, Trikudanathan G, Shen B. Prevalence and risk factors for colonic perforation during colonoscopy in hospitalized inflammatory bowel disease patients. *J Crohns Colitis* 2011; **5**: 189-195 [PMID: 21575880 DOI: 10.1016/j.crohns.2010.12.005] 155. **Rahier JF**, Magro F, Abreu C, Armuzzi A, Ben-Horin S, Chowers Y, Cottone M, de Ridder L, Doherty G, Ehehalt R, Esteve M, Katsanos K, Lees CW, Macmahon E, Moreels T, Reinisch W, Tilg H, Tremblay L, Veereman-Wauters G, Viget N, Yazdanpanah Y, Eliakim R, Colombel JF. Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. *J Crohns Colitis* 2014; **8**: 443-468 [PMID: 24613021 DOI: 10.1016/j.crohns.2013.12.013] 156. **Melmed GY**, Ippoliti AF, Papadakis KA, Tran TT, Birt JL, Lee SK, Frenck RW, Targan SR, Vasiliauskas EA. Patients with inflammatory bowel disease are at risk for vaccine-preventable illnesses. *Am J Gastroenterol* 2006; **101**: 1834-1840 [PMID: 16817843 DOI: 10.1111/j.1572-0241.2006.00646.x] 157. **Selby L**, Kane S, Wilson J, Balla P, Riff B, Bingcang C, Hoellein A, Pande S, de Villiers WJ. Receipt of preventive health services by IBD patients is significantly lower than by primary care patients. *Inflamm Bowel Dis* 2008; **14**: 253-258 [PMID: 17932966 DOI: 10.1002/ibd.20266] 158. **Keene JK**, Lowe DK, Grosfeld JL, Fitzgerald JF, Gonzales-Crussi F. Disseminated varicella complicating ulcerative colitis. *JAMA* 1978; **239**: 45-46 [PMID: 579232 DOI: 10.1001/jama.1978.03280280045025] 159. **Wasan SK**, Baker SE, Skolnik PR, Farraye FA. A practical guide to vaccinating the inflammatory bowel disease patient. *Am J Gastroenterol* 2010; **105**: 1231-1238 [PMID: 20104218 DOI: 10.1038/ajg.2009.733] 160. **Horton HA**, Kim H, Melmed GY. Vaccinations in older adults with gastrointestinal diseases. *Clin Geriatr Med* 2014; **30**: 17-28 [PMID: 24267599 DOI: 10.1016/j.cger.2013.10.002] 161. **Jyrkkä J**, Enlund H, Lavikainen P, Sulkava R, Hartikainen S. Association of polypharmacy with nutritional status, functional ability and cognitive capacity over a three-year period in an elderly population. *Pharmacoepidemiol Drug Saf* 2011; **20**: 514-522 [PMID: 21308855 DOI: 10.1002/pds.2116] 162. **Cahir C**, Fahey T, Teeling M, Teljeur C, Feely J, Bennett K. Potentially inappropriate prescribing and cost outcomes for older people: a national population study. *Br J Clin Pharmacol* 2010; **69**: 543-552 [PMID: 20573091 DOI: 10.1111/j.1365-2125.2010.03628.x] 163. **Siddiqi N**, House AO, Holmes JD. Occurrence and outcome of delirium in medical in-patients: a systematic literature review. *Age Ageing* 2006; **35**: 350-364 [PMID: 16648149 DOI: 10.1093/ageing/afl005] 164. **Alagiakrishnan K**, Wiens CA. An approach to drug induced delirium in the elderly. *Postgrad Med J* 2004; **80**: 388-393 [PMID: 15254302 DOI: 10.1136/pgmj.2003.017236] 165. **Kojima T**, Akishita M, Nakamura T, Nomura K, Ogawa S, Iijima K, Eto M, Ouchi Y. Association of polypharmacy with fall risk among geriatric outpatients. *Geriatr Gerontol Int* 2011; **11**: 438-444 [PMID: 21545384 DOI: 10.1111/j.1447-0594.2011.00703.x] 166. **Boyle N**, Naganathan V, Cumming RG. Medication and falls: risk and optimization. *Clin Geriatr Med* 2010; **26**: 583-605 [PMID: 20934612 DOI: 10.1016/j.cger.2010.06.007] 167. **Sergi G**, De Rui M, Sarti S, Manzato E. Polypharmacy in the elderly: can comprehensive geriatric assessment reduce inappropriate medication use? *Drugs Aging* 2011; **28**: 509-518 [PMID: 21721596 DOI: 10.2165/11592010-000000000-00000] |

**P-Reviewer:** Lee CL, Yu CG **S-Editor:** Kong JX **L-Editor: E-Editor:**

**Table 1 Phenotypic characteristics of inflammatory bowel disease in Elderly- onset inflammatory bowel disease**

|  |  |  |
| --- | --- | --- |
|  | **Crohn’s disease** | **Ulcerative colitis** |
| Location | Colonic or ileo-colonic | Left sided or extensive disease more common than isolated proctitis |
| Symptoms | Less bleeding and abdominal pain than younger patients | Less diarrhoea, abdominal pain and weight loss than younger patients |
| Disease behaviour | Inflammatory; less progression to penetrating and structuring disease | More likely to remain stable |
| First episode | More severe than in younger patients | More severe than in younger patients |
| Extra-intestinal manifestations | Less common than in younger patients | Less common than in younger patients |
| Family history | Less common | Less common |
| Cancer risk | Higher risk of Non-Hodgkin lymphoma with thiopurines and of Non-melanoma skin cancer with anti-TNF therapy | Higher risk of Non-Hodgkin lymphoma with thiopurines and of Non-melanoma skin cancer with anti-TNF therapy |

**Table 2 Differential diagnosis of inflammatory bowel disease**

|  |  |  |
| --- | --- | --- |
| **Disease** | **Clinical Characteristics** | **Additional features** |
| Segmental Colitis Associated with diverticulosis | Diarrhoea with bleeding  Abdominal pain | Segmental peridiverticular distribution  Rectum and proximal colon spared |
| Radiation colitis | Diarrhoea with bleeding and abdominal pain/cramps  Proctitis (urgency and tenesmus)  Symptoms often weeks to years after abdominal or pelvic radiation | Telengiectasia and fibrosis seen at histology |
| NSAID-induced colitis | Diarrhoea with recurrent abdominal pain  Obstruction or perforation  Iron deficiency anaemia | Lesions isolated  Any part of intestine may be affected  Diaphragm like small bowel strictures  Exacerbate existing CD or UC |
| Ischaemic colitis | Sudden onset of abdominal pain  Diarrhoea with bleeding | Segmental distribution of colitis  Typically sigmoid/left sided colitis  Rectum spared and abrupt cut off with non-involved segment |
| Infective colitis | Diarrhoea with bleeding  Constitutional symptoms such as fever | Possible pseudomembranes with Clostridium difficile colitis  Stool cultures usually diagnostic  Rapid resolution with appropriate antibiotic therapy |
| Solitary rectal ulcer | Bleeding per rectum with straining | Mucosal thickening  Crypt architectural distortion  Collagen deposition and smooth muscle in lamina propria |

NSAID: Nonsteroidal anti-inflammatory drug; CD: Crohn’s disease; UC: Ulcerative colitis.

**Table 3 Drug interactions of medications used in the treatment of inflammatory bowel disease relevant to elderly patients**

|  |  |
| --- | --- |
| **IBD Drug** | **Drug Interaction** |
| Aminosalicylates | Increase levels of thiopurine metabolite 6-TGN through weak TPMT inhibition  Interact with warfarin and increase INR (particularly Olsalazine) |
| Metronidazole | Increases levels of: Simvastatin; Calcium channel blockers; sildenafil and lithium  Antabuse (disulfuram) like reaction with ethanol  Increased metabolism and consequent clearance when co-administered with phenytoin and phenobarbitone  Potentiates Warfarin: May increase INR |
| Ciprofloxacin | NSAIDs: Risk of seizures may be increased  Theophylline: Levels may increase  Potentiates Warfarin: May increase INR  Phenytoin: Levels of phenytoin may decrease |
| Corticosteroids | Antidiabetic agents: Hypoglycaemic effects may be decreased  Calcium channel blockers: May increase corticosteroid levels  Diuretics: Hypokalaemic effects increased  Warfarin: May increase anticoagulant effects. |
| Thiopurines | Allopurinol: Can lead to bone marrow toxicity  Aminosalicylates: May lead to increased toxicity and cause leukopenia/myelosuppression  Clotrimazole, angiotensin–converting enzyme inhibitors: increased risk of leucopenia  Warfarin: Anticoagulant effect may decrease |
| Methotrexate | Loop diuretics: Can alter methotrexate concentrations and vice versa  NSAIDs: Bone marrow suppression and gastrointestinal toxicity  Penicillins: Increase methotrexate concentration  Tetracyclines: Increase methotrexate toxicity  Theophylline levels may be increased |
| Cyclosporine | Ciprofloxacin, gentamicin and vancomycin: Potentiate renal dysfunction  Anti-inflammatory drugs and histamine-2 blockers: Potentiate renal dysfunction  Azithromycin, clarithromycin: Increase cyclosporine levels  Allopurinol: Increases cyclosporine levels  Rifampicin: Decreases cyclosporine levels  Phenytoin, phenobarbital and carbamazepine: Decrease levels of cyclosporine.  Grapefruit juice: Increases absorption of cyclosporine |

IBD: Inflammatory bowel disease; NSAIDs: Nonsteroidal anti-inflammatory drugs; 6-TGN: 6-thioguanine nucleotide; TPMT: Thiopurine S-methyltransferase; INR: International normalised ratio.

**Table 4 Live and attenuated vaccines**

|  |  |
| --- | --- |
| **Live** | **Attenuated** |
| Anthrax | Hepatitis B |
| Intranasal influenza | Human papilloma virus |
| Measles-mumps-rubella | Influenza |
| Polio oral vaccine | Pneumococcal |
| Small pox |  |
| Tuberculosis BCG |  |
| Typhoid |  |
| Varicella |  |
| Yellow fever |  |

BCG: Bacille Calmette-Guerin.